Sulfur hexafluoride

Details

Stereochemistry	ACHIRAL
Molecular Formula	F6S
Molecular Weight	146.055
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

FS(F)(F)(F)(F)F

InChI

InChIKey=SFZCNBIFKDRMGX-UHFFFAOYSA-N

InChI=1S/F6S/c1-7(2,3,4,5)6

HIDE SMILES / InChI

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203684s002lbl.pdf | https://imaging.bracco.com/us-en/products/contrast-enhanced-ultrasound/lumason

SULFUR HEXAFLUORIDE is a component of LUMASON® (sulfur hexafluoride lipid-type A microspheres). It is an ultrasound contrast agent indicated for use in the heart echocardiography and in ultrasonography of the liver and the urinary tract. The sulfur hexafluoride lipid microspheres are composed of SF6 gas in the core surrounded by an outer shell monolayer of phospholipids with palmitic acid as a stabilizer.

Approval Year

Conditions

Condition	Modality	Highest Phase	Product
Vesicoureteral reflux 4 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7c679424-c3f7-ed02-892f-20ca0d775089#section-1	Diagnostic	Approved 8429	LUMASON Approved Use Lumason is an ultrasound contrast agent indicated for use - in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult patients with suboptimal echocardiograms - in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients - in ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients Launch Date 2014
Heart Disease 2 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7c679424-c3f7-ed02-892f-20ca0d775089#section-1	Diagnostic	Approved 8429	LUMASON Approved Use Lumason is an ultrasound contrast agent indicated for use - in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult patients with suboptimal echocardiograms - in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients - in ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients Launch Date 2014
Focal liver lesions 2 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7c679424-c3f7-ed02-892f-20ca0d775089#section-1	Diagnostic	Approved 8429	LUMASON Approved Use Lumason is an ultrasound contrast agent indicated for use - in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult patients with suboptimal echocardiograms - in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients - in ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients Launch Date 2014

T_1/2

Value	Dose	Co-administered	Analyte	Population
10 min DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/203684s005lbl.pdf	0.3 mL/kg single, intravenous dose: 0.3 mL/kg route of administration: Intravenous experiment type: SINGLE co-administered:		SULFUR HEXAFLUORIDE blood	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
10.3 mL 1 times / day single, intravenous (mean) Studied dose Dose: 10.3 mL, 1 times / day Route: intravenous Route: single Dose: 10.3 mL, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203684Orig1s000MedR.pdf Page: nda/2014/203684Orig1s000MedR.pdf - p.150	unhealthy, adult n = 5275 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 5275 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203684Orig1s000MedR.pdf Page: nda/2014/203684Orig1s000MedR.pdf - p.150	Other AEs: Nausea, Chest discomfort... Other AEs: Nausea (0.9%) Chest discomfort (0.6%) Chest pain (0.6%) Injection site pain (0.5%) Headache (2.1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203684Orig1s000MedR.pdf Page: nda/2014/203684Orig1s000MedR.pdf - p.150
10.3 mL 1 times / day single, intravenous (mean) Studied dose Dose: 10.3 mL, 1 times / day Route: intravenous Route: single Dose: 10.3 mL, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203684Orig1s000MedR.pdf Page: nda/2014/203684Orig1s000MedR.pdf - p.161	unhealthy, adult n = 5275 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 5275 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203684Orig1s000MedR.pdf Page: nda/2014/203684Orig1s000MedR.pdf - p.161	Disc. AE: Bradycardia, Hypotension... AEs leading to discontinuation/dose reduction: Bradycardia (0.02%) Hypotension (0.04%) Chest pain (0.02%) Electrocardiogram ST segment elevation (0.02%) Hot flush (0.02%) Nausea (0.02%) Swollen tongue (0.02%) Rash (0.02%) Presyncope (0.02%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203684Orig1s000MedR.pdf Page: nda/2014/203684Orig1s000MedR.pdf - p.161
10.3 mL 1 times / day single, intravenous (mean) Studied dose Dose: 10.3 mL, 1 times / day Route: intravenous Route: single Dose: 10.3 mL, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203684Orig1s000MedR.pdf Page: nda/2014/203684Orig1s000MedR.pdf - p.58	unhealthy, adult n = 5275 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 5275 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203684Orig1s000MedR.pdf Page: nda/2014/203684Orig1s000MedR.pdf - p.58	Disc. AE: Injection site vesicles, Cardiac arrest... AEs leading to discontinuation/dose reduction: Injection site vesicles (0.02%) Cardiac arrest (0.02%) Anaphylactic shock (0.02%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203684Orig1s000MedR.pdf Page: nda/2014/203684Orig1s000MedR.pdf - p.58

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
			inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	CYP 270

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP 270	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203684Orig1s000ClinPharmR.pdf#page=29 Page: 29.0	no

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203684Orig1s000PharmR.pdf#page=38 Page: 38.0

Sample Use Guides

In Vivo Use Guide

Echocardiography: After reconstitution, administer LUMASON® 2 mL as an intravenous injection in adult patients. Ultrasonography of the liver in adults: After reconstitution, administer LUMASON® 2.4 mL as an intravenous injection.

Route of Administration: Intravenous

Name

Type

Language

Sulfur hexafluoride

Official Name

English

SULPHUR HEXAFLUORIDE

Systematic Name

English

SULFUR HEXAFLUORIDE [HSDB]

Common Name

English

SULFUR HEXAFLUORIDE [MI]

Common Name

English

LUMASON

Brand Name

English

SULFUR HEXAFLUORIDE [MART.]

Common Name

English

SULFUR FLUORIDE

Systematic Name

English

Sulfur hexafluoride [WHO-DD]

Common Name

English

SULPHUR HEXAFLUORIDE [EMA EPAR]

Common Name

English

SONOVUE

Brand Name

English

BRI

Code

English

SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES [ORANGE BOOK]

Common Name

English

SULFUR HEXAFLUORIDE [USAN]

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000175864